However, an increased anti-tumor efficacy was observed upon treatment with Rituximab and N-803 in immunodeficient mice reconstituted with human NK cells (36) or with Cetuximab and Sushi IL-15-Apo protein in human PBMC reconstituted mice bearing HT-29 colon cancer xenografts (31). This evidence concerns the gene IL15 and colonic neoplasm.